NCT04729621: A trial that was reported late by Teva Pharmaceuticals USA
This trial has reported, although it was 4 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04729621 |
|---|---|
| Title | A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 22, 2021 |
| Completion date | Dec. 31, 2022 |
| Required reporting date | Dec. 31, 2023, midnight |
| Actual reporting date | Jan. 4, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 4 |